Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML

Published:2024-09 Issue: Volume:144 Page:107547
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Wu Shuangshuang,Liu Fangbing,Gai Yuqing,Carter Jenna,Edwards Holly,Hüttemann Maik,Wang Guan,Li Chunhuai,Taub Jeffrey W.,Wang Yue,Ge Yubin

Funder

NW Children's Foundation

RE Children’s Foundation

Jilin Provincial Scientific and Technological Development Program

Publisher

Elsevier BV

Reference38 articles.

1. Acute myeloid leukemia: epidemiology and etiology;Deschler;Cancer,2006

2. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia;Cancer Genome Atlas Research;N. Engl. J. Med,2013

3. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial;Perl;Blood,2022

4. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia;Daver;J. Clin. Oncol.,2022

5. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia;Minson;JCI Insight,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP